The IKK/NF-κB activation pathway -: a target for prevention and treatment of cancer

被引:350
作者
Greten, FR [1 ]
Karin, M [1 ]
机构
[1] Univ Calif San Diego, Sch Med, Dept Pharmacol, Lab Gene Regulat & Signal Transduct, La Jolla, CA 92093 USA
基金
美国国家卫生研究院;
关键词
I kappa B kinase; NF-kappa B; cancer; inflammation; cell cycle; apoptosis; metastasis; therapy;
D O I
10.1016/j.canlet.2003.08.029
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The importance of the IkappaB kinase (IKK)/NF-kappaB signaling pathway in immunoregulatory functions is well accepted. However, the relevance of IKK and NF-kappaB in tumor maintenance, tumor promotion and possibly even in tumor initiation is becoming more evident. Activation of the IKK/NF-kappaB signaling pathway leads to the induction of target genes that can interfere with apoptosis, cell cycle regulation, cell invasion and metastatic growth as well as radio- and chemotherapy. By possibly bridging inflammation and cancer NF-kappaB might also contribute to tumorigenesis. Several natural compounds and synthetic drugs that are able to inhibit the IKK/NF-kappaB activation pathway have been shown to either prevent cancer or to inhibit cell growth in animal models. However, these compounds do not selectively inhibit any of the NF-kappaB;. activation pathways. Furthermore, general inhibition of NF-kappaB might lead to immunodeficiency. The investigation of the different NF-kappaB signaling pathways in different cell types and their role in certain diseases is therefore needed to evaluate the, most successful therapeutic strategies. (C) 2003 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:193 / 199
页数:7
相关论文
共 69 条
[1]   Proteasome inhibition in cancer: Development of PS-341 [J].
Adams, J .
SEMINARS IN ONCOLOGY, 2001, 28 (06) :613-619
[2]   Proteasome inhibition: a novel approach to cancer therapy [J].
Adams, J .
TRENDS IN MOLECULAR MEDICINE, 2002, 8 (04) :S49-S54
[3]   NF-κB activation in cancer:: a challenge for ubiquitination- and proteasome-based therapeutic approach [J].
Amit, S ;
Ben-Neriah, Y .
SEMINARS IN CANCER BIOLOGY, 2003, 13 (01) :15-28
[4]  
Andela VB, 2000, CANCER RES, V60, P6557
[5]   Effects of steroid treatment on activation of nuclear factor κB in patients with inflammatory bowel disease [J].
Ardite, E ;
Panés, J ;
Miranda, M ;
Salas, A ;
Elizalde, JI ;
Sans, M ;
Arce, Y ;
Bordas, JM ;
Fernández-Checa, JC ;
Piqué, JM .
BRITISH JOURNAL OF PHARMACOLOGY, 1998, 124 (03) :431-433
[6]   Inhibition of NF-κB sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin [J].
Arlt, A ;
Vorndamm, J ;
Breitenbroich, M ;
Fölsch, UR ;
Kalthoff, H ;
Schmidt, WE ;
Schäfer, H .
ONCOGENE, 2001, 20 (07) :859-868
[7]   Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB [J].
Baldwin, AS .
JOURNAL OF CLINICAL INVESTIGATION, 2001, 107 (03) :241-246
[8]   Mechanisms of disease - Nuclear factor-kappa b - A pivotal transcription factor in chronic inflammatory diseases [J].
Barnes, PJ ;
Larin, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (15) :1066-1071
[9]   NF-κB transcription factor induces drug resistance through MDR1 expression in cancer cells [J].
Bentires-Alj, M ;
Barbu, V ;
Fillet, M ;
Chariot, A ;
Relic, B ;
Jacobs, N ;
Gielen, J ;
Merville, MP ;
Bours, V .
ONCOGENE, 2003, 22 (01) :90-97
[10]   Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses [J].
Berg, DJ ;
Davidson, N ;
Kuhn, R ;
Muller, W ;
Menon, S ;
Holland, G ;
ThompsonSnipes, L ;
Leach, MW ;
Rennick, D .
JOURNAL OF CLINICAL INVESTIGATION, 1996, 98 (04) :1010-1020